Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JWATM214an Armored GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma a Single-arm, Open-labelDose-escalation Study

Next Previous
Trial Profile

JWATM214an Armored GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma a Single-arm, Open-labelDose-escalation Study

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JWATM-214 (Primary) ; GPC3-CAR-T
  • Indications Liver cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 03 Mar 2023 New trial record
  • 28 Feb 2023 According to JW Therapeutics media release, company announced initiation of JWATM214 in patients with advanced hepatocellular carcinoma (HCC) and first patient infusion.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top